Trexquant Investment LP Has $1.08 Million Holdings in Progyny, Inc. (NASDAQ:PGNY)

Trexquant Investment LP decreased its holdings in shares of Progyny, Inc. (NASDAQ:PGNYFree Report) by 73.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,155 shares of the company’s stock after selling 78,859 shares during the quarter. Trexquant Investment LP’s holdings in Progyny were worth $1,084,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PGNY. RiverPark Advisors LLC increased its position in Progyny by 54.0% during the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock worth $40,000 after purchasing an additional 374 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Progyny during the third quarter worth $53,000. Parkside Financial Bank & Trust lifted its stake in shares of Progyny by 9.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company’s stock valued at $115,000 after acquiring an additional 264 shares during the last quarter. Cetera Trust Company N.A acquired a new stake in shares of Progyny during the 4th quarter valued at $183,000. Finally, Blueshift Asset Management LLC bought a new stake in Progyny during the 3rd quarter worth $238,000. Institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Barclays dropped their target price on Progyny from $48.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, May 13th. Truist Financial cut their target price on shares of Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday, May 17th. Leerink Partnrs restated an “outperform” rating on shares of Progyny in a report on Monday, February 26th. Canaccord Genuity Group decreased their price target on Progyny from $46.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Finally, KeyCorp cut shares of Progyny from an “overweight” rating to a “sector weight” rating in a research report on Friday, May 10th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and a consensus price target of $43.11.

View Our Latest Analysis on Progyny

Insider Transactions at Progyny

In related news, President Michael E. Sturmer sold 4,515 shares of Progyny stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $31.95, for a total value of $144,254.25. Following the completion of the sale, the president now owns 380,038 shares of the company’s stock, valued at approximately $12,142,214.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, President Michael E. Sturmer sold 4,515 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $31.95, for a total value of $144,254.25. Following the sale, the president now owns 380,038 shares in the company, valued at approximately $12,142,214.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman David J. Schlanger sold 71,272 shares of Progyny stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total value of $2,694,081.60. Following the transaction, the chairman now owns 86,312 shares of the company’s stock, valued at approximately $3,262,593.60. The disclosure for this sale can be found here. Insiders have sold 102,770 shares of company stock valued at $3,853,985 over the last ninety days. 12.30% of the stock is owned by company insiders.

Progyny Trading Down 1.4 %

NASDAQ:PGNY opened at $26.30 on Thursday. The firm has a fifty day simple moving average of $32.33 and a two-hundred day simple moving average of $35.27. Progyny, Inc. has a 12 month low of $23.90 and a 12 month high of $44.95. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of 43.11, a PEG ratio of 1.83 and a beta of 1.51.

Progyny (NASDAQ:PGNYGet Free Report) last issued its earnings results on Thursday, May 9th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. The company had revenue of $278.08 million during the quarter, compared to the consensus estimate of $289.41 million. Progyny had a return on equity of 11.61% and a net margin of 5.53%. The firm’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period last year, the business posted $0.18 EPS. Equities analysts predict that Progyny, Inc. will post 0.69 earnings per share for the current fiscal year.

About Progyny

(Free Report)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Articles

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.